P21 (P021)

Evidence Anchor

BioHarmony 5/10

P21 (P021) sits in caution because it pairs the cleanest, broadest rodent neurogenesis-and-tau dataset of any grey-market neurogenic peptide with a completely empty human file and a failed independent replication of its core mechanism. The mouse science is real and worth following: brain-penetrant, orally active, lowering tau, lifting BDNF and neurogenesis across many models. But there are zero human trials, the one independent in-vivo test of the BDNF effect failed, per Mottolese 2024, and nearly all the positive work comes from the inventor, who co-founded the company licensing it, per Kazim 2017. That combination makes the molecule worth following in the literature while it matures, rather than worth self-administering today. The two biggest real-world frictions are the total absence of a human safety baseline and unregulated grey-market sourcing. It is worth saying plainly that the mouse data being genuinely good is what makes this peptide tempting, and it is also why the no-human-evidence line deserves to be loud rather than buried in a footnote. P21 was orally active and crossed the blood-brain barrier in rodents, a genuine pharmacologic strength that most peptides lack, and it lowered tau pathology while lifting hippocampal neurogenesis in Alzheimer's-model mice. That clean preclinical profile is exactly why the missing human data and the failed replication matter so much.Kazim 2014, Neurobiol Dis✅ Best for: People who find the neurogenic mechanism genuinely interesting and want to track it as the literature develops. Anyone who understands that the entire case is preclinical, that the one independent in-vivo replication failed, and that the evidence base is inventor-dominated. Readers comparing it against better-evidenced cognitive options like Cerebrolysin and Semax to see why human data matters. Researchers and clinicians following the Alzheimer's preclinical pipeline. ❌ Avoid if: You want a cognitive intervention with human evidence behind it, because P021 has none. You have active or prior cancer, since chronically raising trophic and pro-proliferative signaling is a theoretical concern with no human safety data. You have a seizure disorder, given the theoretical seizure-threshold concern from neurogenesis modulation. You are pregnant or breastfeeding, with zero safety data. You cannot verify the purity, identity, and sterility of grey-market material, because research-chemical contamination may exceed the intrinsic pharmacological risk of an already untested compound.

Read the full BioHarmony report

My score and my verdict: one signal of three, never the whole answer.